On May 28, QuantumPharm rose 5.09% in regular trading, trading at 8.42 HKD/share, with trading volume of 153 million HKD. The stock continued its upward momentum following multiple positive catalysts.

On the news front, QuantumPharm announced that its collaboration with DoveTree is progressing well, with one pan-cancer high-value asset entering the pre-IND preparation stage, demonstrating clear target intervention effects and an excellent selectivity window. The company received an additional 19 million USD payment under the agreement, having already collected approximately 51 million USD as initial payment in August last year.

Additionally, the three co-founders — Dr. Wen Shuhao, Dr. Ma Jian, and Dr. Lai Lipeng — voluntarily extended their lock-up commitments by an additional 12 months until June 2027, signaling confidence in the company's long-term value. The founders collectively hold approximately 12.9% of issued shares, totaling 555,171,595 shares. The company also recently showcased its AI peptide drug design platform PepiX and generative AI-driven oligonucleotide platform Kodexia at TIDES USA, marking its expansion into multi-modality drug development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)